Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. (ADXS): 9 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
0% dilution
Lead: Phase 3
9 candidates
N/A
N/A
A transparent, data-derived signal for Ayala Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$25.7M
Cash
$4.9M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| ADXS-503 | — |
| ADXS-504 | Phase 1 |
| ADXS-HER2 (ADXS31-164) | Phase 1 |
| ADXS-HOT | — |
| ADXS-NEO | — |
| ADXS-PSA | Phase 2 |
| AT-014 | — |
| AXAL (axalimogene filolisbac / ADXS-HPV) | Phase 3 |
| BST-236 | — |
Frequently asked questions
How many drug candidates are in Ayala Pharmaceuticals, Inc.'s pipeline?
Ayala Pharmaceuticals, Inc. (ADXS) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ayala Pharmaceuticals, Inc.'s market capitalization?
Ayala Pharmaceuticals, Inc.'s market capitalization is approximately $25.7M.
Who is the CEO of Ayala Pharmaceuticals, Inc.?
Mr. Kenneth A. Berlin J.D. is the chief executive officer of Ayala Pharmaceuticals, Inc. (ADXS).
Get the full picture on Ayala Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.